Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Bridgepoint sale of a minority interest in Humanetics
We are advising Bridgepoint and Humanetics on the transaction
Sun Pharmaceutical enters into merger agreement with Taro Pharmaceutical
We are advising Sun Pharma on the transaction
PGT Innovations $3.1 billion acquisition by MITER Brands
We are advising PGT Innovations on the transaction
HashKey Group nearly $100 million Series A financing round
We advised HashKey Group in connection with the transaction
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition
Gersh acquisition of the digital and alternative departments of A3 Artists Agency
We advised Gersh on the acquisition
Myers Industries $350 million acquisition of Signature Systems
We are advising Myers Industries on the acquisition
Cadeler combination with Eneti
We advised Cadeler on the transaction
Williams $1.95 billion acquisition of natural gas storage assets from Hartree
We are advising Williams on the acquisition
MSCI acquisition of Fabric RQ
We are advising MSCI on the acquisition